Multivariate analysis for LFS and OS in 294 patients with MDS who had both cytogenetic and gene mutation data at diagnosis
| . | LFS . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | 95% CI . | 95% CI . | ||||||
| Variable . | HR . | Lower . | Upper . | P . | HR . | Lower . | Upper . | P . |
| Age* | 1.020 | 1.007 | 1.032 | .002 | 1.035 | 1.020 | 1.049 | <.001 |
| IPSS-R† | 1.692 | 1.428 | 2.004 | <.001 | 1.830 | 1.522 | 2.199 | <.001 |
| ASXL1 | 0.972 | 0.617 | 1.530 | .901 | 0.859 | 0.538 | 1.373 | .526 |
| EZH2 | 2.144 | 1.219 | 3.771 | .008 | 2.573 | 1.439 | 4.598 | <.001 |
| RUNX1 | 0.897 | 0.581 | 1.383 | .622 | 0.936 | 0.597 | 1.468 | .773 |
| SF3B1 | 0.513 | 0.264 | 0.999 | .050 | 0.413 | 0.197 | 0.866 | .019 |
| STAG2 | 1.620 | 0.947 | 2.770 | .078 | 1.231 | 0.697 | 2.176 | .474 |
| TP53 | 2.327 | 1.451 | 3.730 | <.001 | 3.365 | 2.056 | 5.508 | <.001 |
| ICCS‡ | 1.303 | 1.120 | 1.515 | .001 | 1.332 | 1.134 | 1.565 | <.001 |
| . | LFS . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | 95% CI . | 95% CI . | ||||||
| Variable . | HR . | Lower . | Upper . | P . | HR . | Lower . | Upper . | P . |
| Age* | 1.020 | 1.007 | 1.032 | .002 | 1.035 | 1.020 | 1.049 | <.001 |
| IPSS-R† | 1.692 | 1.428 | 2.004 | <.001 | 1.830 | 1.522 | 2.199 | <.001 |
| ASXL1 | 0.972 | 0.617 | 1.530 | .901 | 0.859 | 0.538 | 1.373 | .526 |
| EZH2 | 2.144 | 1.219 | 3.771 | .008 | 2.573 | 1.439 | 4.598 | <.001 |
| RUNX1 | 0.897 | 0.581 | 1.383 | .622 | 0.936 | 0.597 | 1.468 | .773 |
| SF3B1 | 0.513 | 0.264 | 0.999 | .050 | 0.413 | 0.197 | 0.866 | .019 |
| STAG2 | 1.620 | 0.947 | 2.770 | .078 | 1.231 | 0.697 | 2.176 | .474 |
| TP53 | 2.327 | 1.451 | 3.730 | <.001 | 3.365 | 2.056 | 5.508 | <.001 |
| ICCS‡ | 1.303 | 1.120 | 1.515 | .001 | 1.332 | 1.134 | 1.565 | <.001 |
P values of <.05 are statistically significant.
Only variables with P value ≤.10 in univariate analysis were incorporated into the multivariate Cox proportional hazard regression analysis.
CI, confidence interval.
Age, as a continuous variable analysis.
IPSS-R risk groups: very good, good, intermediate, poor, very poor.
Immune cell scoring system: low, intermediate, high.